1. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency 
Richard L. Wasserman, MD, PhD, Isaac Melamed, MD, Mark R. Stein, MD, Sudhir Gupta, MD, PhD, Jennifer Puck, MD, Werner Engl, PhD, Heinz Leibl, PhD, Barbara McCoy, PhD, Victoria G. Empson, MSc (Hons), David Gelmont, MD, Richard I. Schiff, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 130, Issue 4, Pages e11 (October 2012)
DOI: /j.jaci
Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Serum IgG concentration for IGHy compared with IGIV and IGSC. Representative pharmacokinetic curves for one subject comparing a 4-week infusion of IGIV, a weekly infusion of IGSC, 10% at 143% of the IV dose with the same data points extended across the 4-week period to facilitate comparison with the other curves, and a 4-week infusion of IGHy at 104% of the IV dose.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig E1 Definitions of mild, moderate, and severe adverse events.
Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci )
Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions